Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance

Backes, James M.; Venero, Carmelo V.; Gibson, Cheryl; Ruisinger, Janelle F.; Howard, Patricia A.; Thompson, Paul D.; Moriarty, Patrick M.

doi:10.1345/aph.1k604

Cited by 116 publications

(74 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Backes et al performed a retrospective analysis on patients taking rosuvastatin (2.5 mg, 5 mg, 10 mg) in 51 patients. Their mean LDL-C decreased by 34.5% on an average dose of rosuvastatin 5.6 mg per mg/dl which also correlates with our findings [11]. In addition, once-a-week dosing using rosuvastatin (2.5 mg-20 mg) also appears to be beneficial.…”

Section: Discussionsupporting

confidence: 89%

Alternate Day Statin Dosing for Women with Previous Statin Intolerance

Minissian¹,

Waldman²,

Shufelt³

et al. 2016

Int J Nurs Clin Pract

View full text Add to dashboard Cite

Background: HMG-CoA reductase inhibitors (statins) are efficacious for treatment and prevention of cardiovascular disease (CVD). Adherence is problematic due to side effects which prevent high risk patients from receiving benefit from statins. Aim: The aim of this study was to evaluate the effectiveness of a nurse practitioner (NP) alternate statin dosing protocol for the reduction of total cholesterol (TC) and low-density lipoprotein (LDL-C). Methods: 15 women who had the inability to tolerate daily dosing were analyzed using a novel NP protocol for initiation and maintenance of alternate dosing utilizing atorvastatin, pravastatin, or rosuvastatin. Patients were started on twice weekly statin dosing for 4 weeks then titrated up one dose per week as tolerated. While on alternate statin dosing, fasting lipid levels were ordered and obtained by chart review. We compared baseline and alternate day dosing by Wilcoxon signed rank test. Results: We evaluated 15 female patients with a mean age of 62 ± 14 years and BMI 26 ± 5 kg/m 2 . Overall, 60% had CVD, 60% had hypertension, 7% had diabetes, and 47% had a history of smoking but currently non-smokers. Prior to the study, all women were intolerant to 2 or more statins. Utilizing the alternate dosing NP protocol, we observed a 32% reduction in LDL-C, to a mean of 84 ± 39 mg/dl compared to the baseline mean of 134 ± 49 mg/dl (p<0.001)and a 20% reduction of TC (p<0.0001). Conclusions: Among women with statin intolerance, an NP statin alternate dosing protocol is effective in reducing TC and LDL-C levels. Further studies using this protocol are warranted in larger statin intolerant populations.

show abstract

Section: Discussionsupporting

confidence: 89%

Alternate Day Statin Dosing for Women with Previous Statin Intolerance

Minissian¹,

Waldman²,

Shufelt³

et al. 2016

Int J Nurs Clin Pract

View full text Add to dashboard Cite

show abstract

“…Rosuvastatin also produced greater reductions in total cholesterol and non HDL-C and produced similar or greater reduction in triglycerides compared to other Statins. 11 Hence the rosuvastatin has been selected for the present study.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of alternate day versus everyday dosing of rosuvastatin in hyperlipidemia

Panchavarthi

Shankara

Pakanati

et al. 2016

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

“…These patients were "rechallenged" with a statin and 92.2 percent were able to remain on treatment 12 months after the initial discontinuation [11]. The Cleveland Clinic Preventive Cardiology Program found that of patients referred who were intolerant to two statins largely because of myalgia, 72.5% could successfully tolerate a third statin [12].…”

Section: Statin Rechallengementioning

confidence: 99%

“…This approach has been based on the concept that some statins, such as rosuvastatin and atorvastatin, have a longer half-life (18-20 h). These statins may maintain their lipid lowering effect over a longer period of time, and thus be administered at wider time intervals [12].…”

Section: Statin Rechallengementioning

confidence: 99%

Clinical Approach to Statin-Induced Adverse Muscle Events: Challenges and Solutions

Nuako¹

2018

J Prev Med

View full text Add to dashboard Cite

Statin-associated adverse muscle events play an important role in statin non adherence and discontinuation. Aspects of this clinical challenge including a lack of a uniform definition of statin-induced myalgia, the "nocebo" effect and its' role in statin-induced adverse muscle events, pre-existing medical and lifestyle factors that can affect statin therapy, and restarting statin use in patients after prior discontinuation of statin therapy due to adverse muscle effects.This paper applies the recommendations of the National Lipid Association's Statin Muscle Safety Task Force along with other studies to propose solutions for these challenges that statin-induced adverse muscle events present. Future large randomized controlled trials will be necessary for validation of these clinical interventions.

show abstract

Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance

Cited by 116 publications

References 21 publications

Alternate Day Statin Dosing for Women with Previous Statin Intolerance

Alternate Day Statin Dosing for Women with Previous Statin Intolerance

Efficacy of alternate day versus everyday dosing of rosuvastatin in hyperlipidemia

Clinical Approach to Statin-Induced Adverse Muscle Events: Challenges and Solutions

Contact Info

Product

Resources

About